Policy Alignment in Life Sciences: Why Entity Structure Can Shape Sunshine Act Risk
Author
May Khan leads the Compliance Services team at Vector Health, a SaaS company focused on life sciences compliance. Her experience includes global transparency reporting, Sunshine Act strategy, and HCP risk monitoring. At Vector, she coordinates cross-functional teams focused on data integrity, customer service, and regulatory alignment.
Vector Health Compliance
Your Leading Partner in Global Sunshine Compliance
Which legal entity is responsible for reporting a transfer of value—the U.S. parent company, its Italian subsidiary, or another entity within the group? For multinational compliance teams, that question can be more complicated than it first appears.
Consider a routine scenario: a global manufacturer sets up a new vendor relationship to support Italian HCP transparency reporting. The vendor contract is signed by a director based in Italy, under the local entity. But the parent company’s finance team still has to determine whether invoicing originates from a European office or a U.S. one, because the contracting and invoicing arrangements can affect how the transaction is recorded internally and which legal entity’s records contain the underlying transfer of value. Those arrangements therefore need to be reconciled with the entity responsible for the relevant transparency reporting obligation. Get this wrong, and the numbers that eventually populate a country’s disclosure register may not map cleanly to the entity legally obligated to report them.
This is what “policy alignment” actually means in practice, not a slogan, but the unglamorous work of making sure corporate structure, contracting authority, tax treatment, and reporting obligations all point to the same answer.
Why This Matters More in Italy Right Now
Italy’s Sunshine Act (Law No. 62/2022) was introduced in June 2022, but its implementing framework, the Sanità Trasparente public register, has taken years to become operational. The Ministry of Health has only recently confirmed that the technical rules are largely finalized, after extended consultation with data protection, anti-corruption, and digital agencies. That long runway has given companies time to prepare, but it has also meant many organizations haven’t yet been forced to stress-test whether their internal entity structures are actually reporting-ready.
Once the relevant reporting framework becomes operational, producer companies will be required to communicate specified transfers of value and other reportable relationships with persons operating in the healthcare sector and healthcare organisations, subject to the conditions and thresholds established by Law No. 62/2022. The law is intended to promote transparency and prevent and combat corruption and degradation of administrative action. If a multinational’s Italian operations run through more than one legal entity, a parent, a branch, a newly forming local SPA, each with different contracting authority and invoicing paths, the reporting process can become difficult to manage unless the relevant entity responsibilities and data flows are resolved in advance.
Where Alignment Breaks Down
In our experience working with life sciences companies expanding transparency programs into new markets, misalignment tends to show up in three places:
- Contracting authority vs. reporting entity: the signatory on a vendor or HCP agreement isn’t always the entity whose books ultimately reflect the transfer of value.
- Invoicing and tax treatment: cross-border invoicing arrangements can affect VAT and withholding-tax considerations, which should be reconciled with how the underlying transfer of value is recorded and reported.
- New entity formation lag: companies mid-process of establishing a local entity often need to manage a transition period where a regional entity temporarily handles functions the local entity will eventually own.
None of these are exotic edge cases. They’re the ordinary mechanics of doing business across borders, and exactly the kind of ambiguity that turns into a reporting gap if nobody owns the resolution before the first disclosure deadline arrives.
Building Alignment Into the Process, Not After It
The companies handling this well tend to do one thing consistently: they resolve entity and invoicing questions during vendor and contract setup, not after data collection has already begun. That means looping in finance, legal, and compliance early enough to answer “who reports this, and under which entity” before the first transfer of value is even booked.
Getting this right doesn’t just reduce audit risk. It gives compliance and finance teams a shared, defensible answer they can point to when regulators, or the public register itself, ask where a number came from.
Which legal entity is responsible for reporting a transfer of value—the U.S. parent company, its Italian subsidiary, or another entity within the group? For multinational compliance teams, that question can be more complicated than it first appears.
Consider a routine scenario: a global manufacturer sets up a new vendor relationship to support Italian HCP transparency reporting. The vendor contract is signed by a director based in Italy, under the local entity. But the parent company’s finance team still has to determine whether invoicing originates from a European office or a U.S. one, because the contracting and invoicing arrangements can affect how the transaction is recorded internally and which legal entity’s records contain the underlying transfer of value. Those arrangements therefore need to be reconciled with the entity responsible for the relevant transparency reporting obligation. Get this wrong, and the numbers that eventually populate a country’s disclosure register may not map cleanly to the entity legally obligated to report them.
This is what “policy alignment” actually means in practice, not a slogan, but the unglamorous work of making sure corporate structure, contracting authority, tax treatment, and reporting obligations all point to the same answer.
Why This Matters More in Italy Right Now
Italy’s Sunshine Act (Law No. 62/2022) was introduced in June 2022, but its implementing framework, the Sanità Trasparente public register, has taken years to become operational. The Ministry of Health has only recently confirmed that the technical rules are largely finalized, after extended consultation with data protection, anti-corruption, and digital agencies. That long runway has given companies time to prepare, but it has also meant many organizations haven’t yet been forced to stress-test whether their internal entity structures are actually reporting-ready.
Once the relevant reporting framework becomes operational, producer companies will be required to communicate specified transfers of value and other reportable relationships with persons operating in the healthcare sector and healthcare organisations, subject to the conditions and thresholds established by Law No. 62/2022. The law is intended to promote transparency and prevent and combat corruption and degradation of administrative action. If a multinational’s Italian operations run through more than one legal entity, a parent, a branch, a newly forming local SPA, each with different contracting authority and invoicing paths, the reporting process can become difficult to manage unless the relevant entity responsibilities and data flows are resolved in advance.
Where Alignment Breaks Down
In our experience working with life sciences companies expanding transparency programs into new markets, misalignment tends to show up in three places:
- Contracting authority vs. reporting entity: the signatory on a vendor or HCP agreement isn’t always the entity whose books ultimately reflect the transfer of value.
- Invoicing and tax treatment: cross-border invoicing arrangements can affect VAT and withholding-tax considerations, which should be reconciled with how the underlying transfer of value is recorded and reported.
- New entity formation lag: companies mid-process of establishing a local entity often need to manage a transition period where a regional entity temporarily handles functions the local entity will eventually own.
None of these are exotic edge cases. They’re the ordinary mechanics of doing business across borders, and exactly the kind of ambiguity that turns into a reporting gap if nobody owns the resolution before the first disclosure deadline arrives.
Building Alignment Into the Process, Not After It
The companies handling this well tend to do one thing consistently: they resolve entity and invoicing questions during vendor and contract setup, not after data collection has already begun. That means looping in finance, legal, and compliance early enough to answer “who reports this, and under which entity” before the first transfer of value is even booked.
Getting this right doesn’t just reduce audit risk. It gives compliance and finance teams a shared, defensible answer they can point to when regulators, or the public register itself, ask where a number came from.
Author
May Khan leads the Compliance Services team at Vector Health, a SaaS company focused on life sciences compliance. Her experience includes global transparency reporting, Sunshine Act strategy, and HCP risk monitoring. At Vector, she coordinates cross-functional teams focused on data integrity, customer service, and regulatory alignment.
Vector Health Compliance
Your Leading Partner in Global Sunshine Compliance